PCA3 Molecular Urine Assay Correlates With Prostate Cancer Tumor Volume: Implication in Selecting Candidates for Active Surveillance

Journal of Urology

Volumn 179, Issue 5, 2008, Pages 1804-1810

  Nakanishi, Hiroyuki ^a   Groskopf, Jack ^b   Fritsche, Herbert A ^a   Bhadkamkar, Viju ^a   Blase, Amy ^b   Kumar, S Vikas ^a   Davis, John W ^a   Troncoso, Patricia ^a   Rittenhouse, Harry ^b   Babaian, R Joseph ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Gen Probe Incorporated   (United States)

Author keywords

genes; neoplasm; prostate specific antigen; prostatic neoplasms

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; HEALTH SURVEY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; ONCOGENE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; PROSTATECTOMY; TUMOR VOLUME; URINALYSIS;

AGED; ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 41749088455     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.01.013     Document Type: Article

References (19)

1. Catalona W.J., Smith D.S., Ratliff T.L., Dodds K.M., Coplen D.E., Yuan J.J., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156
2. Loeb S., Gonzalez C.M., Roehl K.A., Han M., Antenor J.A., Yap R.L., et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 175 (2006) 902
3. Stamey T.A., Freiha F.S., McNeal J.E., Redwine E.A., Whittemore A.S., and Schmid H.P. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71 (1993) 933
4. Klotz L. Active surveillance for prostate cancer: for whom?. J Clin Oncol 23 (2005) 8165
5. Ochiai A., Troncoso P., and Babaian R.J. The relationship between serum prostate specific antigen level and tumor volume persists in the current era. J Urol 177 (2007) 903
6. Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M., and Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297
7. Bradford T.J., Tomlins S.A., Wang X., and Chinnaiyan A.M. Molecular markers of prostate cancer. Urol Oncol 24 (2006) 538
8. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., Smit F.P., Karthaus H.F., Schalken J.A., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59 (1999) 5975
9. de Kok J.B., Verhaegh G.W., Roelofs R.W., Hessels D., Kiemeney L.A., Aalders T.W., et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62 (2002) 2695
10. Hessels D., Klein Gunnewiek J.M., van Oort I., Karthaus H.F., van Leenders G.J., van Balken B., et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44 (2003) 8
11. Groskopf J., Aubin S.M., Deras I.L., Blasé A., Bodrug S., Clark C., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089
12. Marks L.S., Fradet Y., Deras I.L., Blasé A., Mathis J., Aubin S.M., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69 (2007) 532
13. van Gils M.P., Hessels D., van Hooij O., Jannink S.A., Peelen W.P., Hanssen S.L., et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 13 (2007) 939
14. Ochiai A., Troncoso P., Chen M.E., Lloreta J., and Babaian R.J. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management. J Urol 174 (2005) 2164
15. Meng F.J., Shan A., Jin L., and Young C.Y. The expression of a variant prostate-specific antigen in human prostate. Cancer Epidemiol Biomarkers Prev 11 (2002) 305
16. Babaian R.J., Troncoso P., Bhadkamkar V.A., and Johnston D.A. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer 91 (2000) 1414
17. Chen M.E., Johnson D., Reyes A.O., Soto C.P., Babaian R.J., and Troncoso P. A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 27 (2003) 1291
18. Epstein J.I., Chan D.W., Sokoll L.J., Walsh P.C., Cox J.L., Rittenhouse H., et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160 (1998) 2407
19. Tinzl M., Marberger M., Horvath S., and Chypre C. DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol 46 (2004) 182